Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | MGLL | Q99685 | 1/20 | 0.45 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1365835 | 1.00 | ALDH1A1 (0.58) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A | |
| SCHEMBL18762322 | 1.00 | ALDH1A1 (0.58) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A | |
| SCHEMBL3871093 | 1.00 | ALDH1A1 (0.58) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A | |
| SCHEMBL24677830 | 1.00 | ALDH1A1 (0.58) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A | |
| SCHEMBL1419528 | 1.00 | ALDH1A1 (0.58) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A | |
| SCHEMBL24678064 | 1.00 | ALDH1A1 (0.58) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A | |
| SCHEMBL7545592 | 1.00 | ALDH1A1 (0.58) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A | |
| SCHEMBL5386843 | 1.00 | ALDH1A1 (0.58) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A | |
| SCHEMBL318699 | 1.00 | ALDH1A1 (0.58) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A | |
| SCHEMBL1363586 | 0.98 | ALDH1A1 (0.59) | ALDH1A1MAPK1L3MBTL1TDP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117903225-A | Liver tissue targeted delivery compound, preparation method and application thereof | 思合基因(北京)生物科技有限公司 | 2024-04-19 | — | — | CN | disclosed |
| US-11833208-B2 | PLK1 selective degradation inducing compound | UPPTHERA, INC. (KR) | 2023-12-05 | — | — | US | disclosed |
| US-11833208-B2 | PLK1 selective degradation inducing compound | UPPTHERA, INC. (KR) | 2023-12-05 | — | — | US | disclosed |
| US-20230372498-A1 | PLK1 SELECTIVE DEGRADATION INDUCING COMPOUND | UPPTHERA (KR) | 2023-11-23 | — | — | US | disclosed |
| US-20230372498-A1 | PLK1 SELECTIVE DEGRADATION INDUCING COMPOUND | UPPTHERA (KR) | 2023-11-23 | — | — | US | disclosed |
| EP-3476832-B1 | CATIONIC LIPID | EISAI R&D MAN CO LTD (JP) | 2023-04-19 | — | — | EP | disclosed |
| EP-3733647-B1 | CATIONIC LIPID | EISAI R&D MAN CO LTD (JP) | 2022-06-15 | — | — | EP | disclosed |
| EP-3733647-B1 | CATIONIC LIPID | EISAI R&D MAN CO LTD (JP) | 2022-06-15 | — | — | EP | disclosed |
| CN-109311809-B | Cationic lipids | 卫材R&D管理有限公司 | 2022-04-08 | — | — | CN | disclosed |
| EP-2880012-B1 | COMPOUNDS | PHOTOCURE ASA (NO) | 2021-12-15 | — | — | EP | disclosed |
| WO-2005121904-A1 | CHARGE CONTROL AGENT, TONER, IMAGE FORMING METHOD, AND IMAGE FORMING APPARATUS | CANON KABUSHIKI KAISHA (JP) | 2005-12-22 | — | — | WO | disclosed |
| EP-1105399-B1 | CARBOXYLATED PHOSPHATIDIC ACID ESTERS | BRACCO RESEARCH SA (CH) | 2004-04-14 | — | — | EP | disclosed |
| US-6706280-B2 | DRUG TARGETING WITH LIPOSOMES AND MAGNETIC RESONANCE IMAGING CONTRAST MEDIA FOR DIAGNOSTICS | BRACCO RESEARCH S.A. (CH) | 2004-03-16 | — | — | US | disclosed |
| US-20020136760-A1 | CARBOXYLATED PHOSPHATIDIC ACID ESTERS | BRACCO RESEARCH S.A. (CH) | 2002-09-26 | — | — | US | disclosed |
| EP-1105399-A1 | CARBOXYLATED PHOSPHATIDIC ACID ESTERS | BRACCO RESEARCH S.A. (CH) | 2001-06-13 | — | — | EP | disclosed |
| WO-2000011007-A1 | CARBOXYLATED PHOSPHATIDIC ACID ESTERS | BRACCO RESEARCH S.A. (CH) | 2000-03-02 | — | — | WO | disclosed |
| US-5846954-A | Cyclodextrin compounds and methods of making and use thereof | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1998-12-08 | — | — | US | disclosed |
| US-5760015-A | FOR MODULATING CELLULAR GROWTH ACTIVITY | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1998-06-02 | — | — | US | disclosed |
| EP-0824352-A1 | CYCLODEXTRIN COMPOUNDS AND METHODS OF MAKING AND USE THEREOF | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1998-02-25 | — | — | EP | disclosed |
| WO-1996031220-A1 | CYCLODEXTRIN COMPOUNDS AND METHODS OF MAKING AND USE THEREOF | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1996-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372498-A1 | PLK1 SELECTIVE DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | ALDH1A1 3592/4885MAPK1 1316/4885L3MBTL1 719/4885 |
| US-20020136760-A1 | CARBOXYLATED PHOSPHATIDIC ACID ESTERS | PHOSPHO1, PLD1, SGMS1 | ALDH1A1 1522/4885MAPK1 2643/4885L3MBTL1 1472/4885 |
| US-11833208-B2 | PLK1 selective degradation inducing compound | PLK1, BUB1B, BUB1 | ALDH1A1 3592/4885MAPK1 1316/4885L3MBTL1 719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.